Cavalcante Ludimila L, Cavalcante Milena L, Murray Timothy G, Vigoda Michael M, Piña Yolanda, Decatur Christina L, Davis R Prince, Olmos Lisa C, Schefler Amy C, Parrott Michael B, Alliman Kyle J, Flynn Harry W, Moshfeghi Andrew A
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School, of Medicine, Miami, FL, USA.
Clin Ophthalmol. 2010 May 25;4:519-24. doi: 10.2147/opth.s11094.
To report the incidence of endophthalmitis, in addition to its clinical and microbiological aspects, after intravitreal injection of vascular-targeting agents.
A retrospective review of a consecutive series of 10,142 intravitreal injections of vascular targeting agents (bevacizumab, ranibizumab, triamcinolone acetonide, and preservative-free triamcinolone acetonide) between June 1, 2007 and January 31, 2010, performed by a single service (TGM) at the Bascom Palmer Eye Institute.
One case of clinically-suspected endophthalmitis was identified out of a total of 10,142 injections (0.009%), presenting within three days of injection of bevacizumab. The case was culture-positive for Staphylococcus epidermidis. Final visual acuity was 20/40 after pars plana vitrectomy surgery.
In this series, the incidence of culture-positive endophthalmitis after intravitreal injection of vascular agents in an outpatient setting was very low. We believe that following a standardized injection protocol, adherence to sterile techniques and proper patient follow-up are determining factors for low incidence rates.
报告玻璃体内注射血管靶向药物后眼内炎的发生率及其临床和微生物学特征。
对2007年6月1日至2010年1月31日期间，由巴斯科姆·帕尔默眼科研究所的单一科室（TGM）连续进行的10142次玻璃体内注射血管靶向药物（贝伐单抗、雷珠单抗、曲安奈德和无防腐剂曲安奈德）进行回顾性研究。
在总共10142次注射中，发现1例临床疑似眼内炎（0.009%），在注射贝伐单抗后三天内出现。该病例表皮葡萄球菌培养呈阳性。经扁平部玻璃体切除术后，最终视力为20/40。
在本系列研究中，门诊环境下玻璃体内注射血管药物后培养阳性眼内炎的发生率非常低。我们认为，遵循标准化注射方案、坚持无菌技术和对患者进行适当随访是发生率低的决定性因素。
